Introduction
============

Acute exacerbation is a common phenomenon for chronic obstructive pulmonary disease (COPD) patients during the course of their disease.[@b1-copd-11-2729] Acute exacerbations of COPD (AECOPD) impact long-term prognosis and are associated with substantial in-hospital mortality. The most important factors that determine the overall prognosis of COPD are the frequency and severity of exacerbations;[@b2-copd-11-2729],[@b3-copd-11-2729] and AECOPD are often companied with respiratory failure.[@b1-copd-11-2729] The blood of most of AECOPD patients is in a hypercoagulable state for hypoxemia and carbon dioxide retention.[@b4-copd-11-2729]--[@b6-copd-11-2729] This state causes the formation of small pulmonary thrombosis and leads to an adverse prognosis.[@b7-copd-11-2729]--[@b9-copd-11-2729] Some clinical evidence shows that hypercoagulable state and thrombosis in the pulmonary vessels can alter the clinical course of patients with COPD, especially during the period of acute exacerbations.[@b10-copd-11-2729] The D-dimer is a product of fibrinolysis, which may increase during many illnesses and physiological conditions associated with thrombosis and thrombolysis.[@b11-copd-11-2729] Studies have showed that elevated plasma D-dimer was associated with adverse outcomes, and D-dimer has been recommended as a prognostic factor for these conditions.[@b10-copd-11-2729],[@b12-copd-11-2729]--[@b17-copd-11-2729] However, there are few prospective studies that have investigated the role of D-dimer in patients with exacerbations of COPD. We therefore performed a prospective study to investigate the role of serum D-dimer in the prediction of in-hospital mortality and all-cause mortality within 1 year in AECOPD patients.

Methods
=======

Subjects
--------

We screened all the AECOPD patients admitted to the respiratory medicine department of the Third Affiliated Hospital of Guangzhou Medical University (Guangzhou, People's Republic of China) from November 2012 to November 2014. All subjects had been diagnosed with COPD previously by respiratory doctors. The exclusion criteria were: hospitalization for a reason other than AECOPD, inability or unwillingness to cooperate with the doctors, and not providing spirometry data. We invited all the AECOPD patients to participate in the present study on the first day of admission to the ward. The ethics committee of The Third Affiliated Hospital of Guangzhou Medical University approved the research protocol.

Study design
------------

Patient demographics, including age, sex, the number of hospitalizations for AECOPD in the previous year, smoking habit, and comorbidities, with a special emphasis on cardiovascular disease, were recorded. Clinical data, such as vital signs and arterial blood gases (pH, arterial carbon dioxide tension (PaCO~2~), arterial oxygen tension (PaO~2~), and arterial oxygen saturation), were examined on admission. We collected the blood samples from each patient at the time of admission to the department of respiratory disease for D-dimer and standard laboratory measurements (creatinine, blood urea nitrogen (BUN), platelets, hemoglobin, hematocrit, fibrinogen, and C-reactive protein (CRP)). The glomerular filtration rate (GFR) was calculated within 24 hours of admission by the simplified modification of diet in renal disease equation.[@b18-copd-11-2729] GFR \<90 mL/min/1.73 m^2^ was considered as renal dysfunction. Congestive heart failure was diagnosed on the base of the Chinese guidelines published in 2007 for the diagnosis and management of chronic heart failure.[@b19-copd-11-2729] Attending physicians not involved in this study made the treatment programs according to the Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines.[@b1-copd-11-2729] Patients were followed up with telephone interviews every 3 months for 1 year by the study investigators. Patients with at least one hospitalization for AECOPD in the previous year were considered as frequent exacerbators.

Statistical analysis
--------------------

The primary outcomes were in-hospital and all-cause mortality at 1 year. The secondary outcome was the factors associated with in-hospital death. Categorical variables are presented as n (%), and normally distributed values are presented as mean ± standard deviation. Comparisons between groups were made using chi-squared test (for categorical variables) or analysis of variance (for continuous variables). Receiver operator curve analysis was applied to define the minimal optimal D-dimer level that predicted death. Multivariate logistic regression analysis was applied to determine the independent factors of in-hospital death. To evaluate the influence of D-dimer levels on 1-year mortality, we performed Cox regression univariate and multivariate analyses. Significant confounders, including age, sex, current smoking status, the comorbidities of heart failure and renal dysfunction, pH, PaO~2~, PaCO~2~, and GOLD stage, were evaluated in the Cox regression analyses. Kaplan--Meier survival curves and log-rank tests were used to compare the time to death between those with elevated D-dimer levels and those without. The results are presented as hazard ratios (HRs) with 95% confidence interval (CI). We analyzed the data using the Stata statistical software package (Version 7.0, Stata Corporation, College Station, TX, USA) and SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

D-dimer and in-hospital mortality
---------------------------------

We evaluated 391 AECOPD patients. However, there were only 343 AECOPD patients included in our study. [Figure 1](#f1-copd-11-2729){ref-type="fig"} shows the flow chart of the included participants. Twenty-eight subjects experienced in-hospital mortality. [Table 1](#t1-copd-11-2729){ref-type="table"} shows the differences between survivors and non-survivors in the hospital. There were more patients who suffered from renal dysfunction and congestive heart failure in the non-survivor group. Additionally, the non-survivors were significantly older (80.4±8.1 years old) and more hypercapnic (PaCO~2~: 58.8±29.7 mmHg) than the survivors (PaCO~2~: 46.1±27.0 mmHg and 75.8±9.9 years old, respectively). There was no difference in lung function, fibrinogen, platelets, PaO~2~, or hematocrit between survivors and those who died. The pH was significantly lower in the patients who died (pH: 7.346±0.106) compared to survivors (pH: 7.389±0.054). The plasma levels of D-dimer, CRP, and BUN were higher in non-survivors (D-dimer: 2,244.9±2,310.7 ng/L, CRP 81.5±66.0 mg/L, and BUN 10.2±6.87 mmol/L) than in survivors (D-dimer: 768.2±1,078.4 ng/L, CRP: 42.0±56.2 mg/L, and BUN: 6.15±3.15 mmol/L).

Associations between Serum D-dimer levels and clinically relevant outcomes
--------------------------------------------------------------------------

[Figure 2](#f2-copd-11-2729){ref-type="fig"} shows that the area under the curve of serum D-dimer to predict in-hospital death was 0.748 (95% CI 0.641--0.854), and the cutoff point 985 ng/L, with a sensitivity of 0.714 and a specificity of 0.794. According to the serum D-dimer levels, the entire cohort was divided into two groups. There were 85 patients with D-dimer levels ≥985 ng/L and 258 with D-dimer levels \<985 ng/L. [Table 2](#t2-copd-11-2729){ref-type="table"} shows non-statistically significant associations of D-dimer levels with sex, PaCO~2~, pH, fibrinogen, platelets, and PaO~2~ (*P*\>0.05) and statistically significant associations with age, renal dysfunction, hemoglobin, hematocrit, CRP, and the concentration of creatinine and BUN (*P*\<0.05).

Serum D-dimer levels and in-hospital mortality
----------------------------------------------

Univariate analyses ([Table 3](#t3-copd-11-2729){ref-type="table"}) showed that a pH \<7.35, PaCO~2~ ≥50 mmHg, PaO~2~ \<60 mmHg, congestive heart failure, renal dysfunction, and D-dimer ≥985 ng/L were risk factors of in-hospital mortality, while age, GOLD stage, sex, and frequent exacerbators in the past year were not risk factors for in-hospital mortality. However, multivariate logistic regression analysis only showed that congestive heart failure and D-dimer ≥985 ng/L were associated with in-hospital mortality ([Table 4](#t4-copd-11-2729){ref-type="table"}).

Serum D-dimer levels and 1-year mortality
-----------------------------------------

Fifty-seven subjects died within 1 year. [Figure 3](#f3-copd-11-2729){ref-type="fig"} shows the Kaplan--Meier survival curves, which evaluated the time to death within 1 year based on serum D-dimer levels. Patients with serum D-dimer ≥985 ng/L had an increased risk of 1-year mortality compared to those with serum D-dimer \<985 ng/L. Univariate Cox regression analyses showed that D-dimer was a risk factor for 1-year mortality (HR 3.48, 95% CI 2.07--5.85; *P*=0.001) ([Table 5](#t5-copd-11-2729){ref-type="table"}). And multivariate analysis also showed that the serum D-dimer level still was an independent risk factor of 1-year mortality (HR 1.96, 95% CI 1.05--3.65; *P*=0.035).

Univariate analyses ([Table 5](#t5-copd-11-2729){ref-type="table"}) showed that age, pH \<7.35, PaCO~2~ ≥50 mmHg, PaO~2~ \<60 mmHg, congestive heart failure, renal dysfunction, CRP, and D-dimer ≥985 ng/L were risk factors of 1-year death, and GOLD stage, sex, and frequent exacerbators in the past year were not associated with 1-year death. Multivariate analysis confirmed that CRP, congestive heart failure, renal dysfunction, and D-dimer ≥985 ng/L were risk factors of 1-year death ([Table 5](#t5-copd-11-2729){ref-type="table"}).

Discussion
==========

This study is a comprehensive prospective study reporting the associations between D-dimer levels and in-hospital and 1-year mortality for COPD exacerbation. In the present study, our result showed that the serum D-dimer level was an independent risk factor for in-hospital death (relative risk =6.51, 95% CI: 3.06--13.83) and 1-year mortality (HR =3.48, 95% CI 2.07--5.85; *P*=0.001 for univariate analysis; and HR =1.96, 95% CI 1.05--3.65; *P*=0.035 for multivariate analysis) for AECOPD. Many studies have reported that the D-dimer was an independent predictor for cardiovascular and all-cause death among elderly persons.[@b10-copd-11-2729],[@b13-copd-11-2729],[@b15-copd-11-2729],[@b20-copd-11-2729] Our study results were consistent with the retrospective study reported by Oren Fruchter,[@b10-copd-11-2729] which showed that D-dimer level examined on admission could be used as a predictive biomarker for short-and long-term mortality for AECOPD.[@b10-copd-11-2729]

Several factors have been previously reported to be risk factors for death, including the frequency of AECOPD.[@b21-copd-11-2729] Soler-Cataluna et al have reported that frequent exacerbations were a risk factor for mortality.[@b21-copd-11-2729] However, in the present study, we found that frequent exacerbations were not a risk factor for in-hospital or 1-year mortality. The differing outcomes between studies may be related to the dissimilar definitions of frequent exacerbators. In our study, we could not collect the exact data on the exacerbations in the past year. But, we could collect the previous year's information of hospitalization due to AECOPD; therefore, frequent exacerbators were defined as patients who had at least one hospitalization for AECOPD in the past year. We did find that AECOPD patients with coexisting congestive heart failure had higher 1-year and in-hospital death, which was consistent with previous studies.[@b22-copd-11-2729],[@b23-copd-11-2729]

In our study, we found that elevated CRP was an unfavorable factor for both 1-year and in-hospital death for AECOPD. There are some studies that have reported that elevated HsCRP was a risk factor for adverse outcomes of AECOPD.[@b24-copd-11-2729],[@b25-copd-11-2729] Of course, there are also studies that showed that elevated HsCRP was not associated with mortality of AECOPD.[@b26-copd-11-2729] In a previous study from our group, we showed that plasma cystatin C was a risk factor for in-hospital mortality.[@b27-copd-11-2729] Additionally, in another study from our group, the PSI index was associated with in-hospital death.[@b28-copd-11-2729] D-dimer was an easy-to-obtain biomarker and an independent risk factor of in-hospital and 1-year mortality, which suggest that D-dimer could be used to identify serious patients who need more intensive treatment. So, serum D-dimer levels could be used to construct a multicomponent score in future studies.

Additionally, we also explored the association between D-dimer levels with laboratory tests and clinical characteristics for AECOPD patients. We found that D-dimer levels were higher in patients with renal dysfunction and congestive heart failure and were associated with CRP, hemoglobin, hematocrit, and old age. Alternatively, D-dimer was not associated with sex, PaCO~2~, pH, fibrinogen, platelets, and PaO~2~. Ya-Jun Song et al have reported that the serum D-dimer levels significantly negatively related to PaO~2~ and positively related to PaCO~2~ in the patients with AECOPD combined with respiratory failure.[@b29-copd-11-2729] There were also some studies that showed D-dimer levels in patients with renal dysfunction were elevated.[@b30-copd-11-2729],[@b31-copd-11-2729] The study by Jafri et al showed that D-dimer levels in patients with heart failure were higher than patients without heart failure.[@b32-copd-11-2729]

Our study has several limitations. The first is that pulmonary embolism, diagnosed by computed tomography pulmonary angiography (CTPA) or pulmonary angiography, was not excluded, which may generate bias. The second limitation is that the patients were followed up only by telephone and every 3 months, which may generate interview bias. The third limitation is that we could not collect the exacerbation times in the past years. The frequent exacerbators were defined as patients with at least one hospitalization for AECOPD in the previous year.

Conclusion
==========

Conclusively, D-dimer was a risk predictor both for in-hospital and 1-year mortality of AECOPD patients. Additionally, the serum D-dimer is a widely and rapidly examined cheaper biomarker, which means that D-dimer could be used to identify serious AECOPD patients.
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![A ROC curve of plasma D-dimer as an overall predictor of death in AECOPD patients.\
**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; AUC, area under receiver operator characteristic curve; CI, confidence interval; ROC, receiver operator characteristic.](copd-11-2729Fig2){#f2-copd-11-2729}

![Kaplan--Meier survival curves evaluating the time to death in days for patients with D-dimer levels above (≥985 ng/L) and below (\<985 ng/L) the median value (*P*=0.000 by log-rank test).](copd-11-2729Fig3){#f3-copd-11-2729}

###### 

Baseline characteristics and survival of patients hospitalized with AECOPD

  Patients characteristics    Alive (315)     Dead (28)         *F/X*^2^   *P*-value
  --------------------------- --------------- ----------------- ---------- -----------
  Age                         75.8±9.9        80.4±8.1          5.688      0.018
  Gender (male/female)        203/112         20/8              0.551      0.458
  *Smoker (no/ever/yes)*      *97/172/46*     *10/13/5*         *0.701*    *0.704*
  Malignancy (yes/no)         *18/297*        3/25              *1.118*    *0.240*
  *%FEV~1~*                   *51.6*±20.9     *52.0*±16.2       *0.008*    *0.929*
  *CHF (no/yes)*              *270/45*        *13/15*           *27.498*   \<0.0001
  RD (no/yes)                 285/29          16/12             *27.542*   \<0.0001
  PaCO~2~ (mmHg)              46.1±27.0       58.8±29.7         *5.657*    *0.018*
  PaO~2~ (mmHg)               85.4±41.9       75.5±25.0         1.5        0.221
  pH                          7.389±0.054     7.346±0.106       *13.597*   \<0.0001
  D-dimer (ng/L)              768.2±1,078.4   2,244.9±2,310.7   *37.545*   \<0.0001
  Creatinine (µmmol/L)        88.81±45.63     100.43±53.26      *1.619*    *0.204*
  BUN (mmol/L)                6.15±3.15       10.20±6.87        32.705     \<0.0001
  CRP (mg/L)                  42.0±56.2       81.5±66.0         12.271     0.001
  Blood platelet (10^−9^/L)   226.1±74.1      221.8±86.3        0.083      0.773
  Hemoglobin (g/L)            128.3±18.2      118.6±29.4        6.544      0.011
  Hematocrit (%)              39.2±5.2        37.5±8.6          2.375      0.124
  Fibrinogen (g/L)            3.71±1.09       3.91±1.38         0.845      0.359

**Note:** Italics indicate significance.

**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; BUN, blood urea nitrogen; CHF, congestive heart failure; CRP, C-reactive protein; PaO~2~, arterial oxygen tension; PaCO~2~, arterial carbon dioxide tension; RD, renal dysfunction.

###### 

Baseline characteristics stratified by the D-dimer concentration

  Patients characteristics   D-dimer ≥985 (µg/L)   D-dimer \<985 (µg/L)   *F/X*^2^   *P*-value
  -------------------------- --------------------- ---------------------- ---------- -----------
  Patient                    85                    258                               
  Age                        81.7±8.0              74.3±9.7               40.781     *0.000*
  Gender (male/female)       56/29                 167/91                 0.037      0.847
  PaCO~2~ (mmHg)             48.1±20.9             46.7±29.2              0.171      *0.679*
  PaO~2~ (mmHg)              78.2±25.8             86.6±44.4              2.627      *0.106*
  pH                         7.38±0.09             7.39±0.05              2.657      *0.104*
  CHF (yes/no)               21/64                 39/219                 4.074      *0.044*
  RD (yes/no)                22/63                 19/239                 20.832     *0.000*
  Hemoglobin                 116.2±20.8            131.2±17.5             42.552     *0.000*
  Hematocrit                 36.26±6.06            40.0±5.09              30.75      *0.000*
  CRP                        64.2±63.7             39.0±54.7              12.239     *0.001*
  Creatinine (µmmol/L)       100.5±64.2            86.2±38.1              6.151      *0.014*
  BUN (mmol/L)               8.12±5.41             5.94±2.82              22.890     0.000
  Fibrinogen                 3.89±1.27             3.67±1.05              2.371      *0.124*
  Blood platelet             228.8±88.4            224.7±70.2             0.191      *0.663*

**Abbreviations:** BUN, blood urea nitrogen; CHF, congestive heart failure; CRP, C-reactive protein; PaCO~2~, arterial carbon dioxide tension; PaO~2~, arterial oxygen tension; RD, renal dysfunction.

###### 

Hospital-mortality risk in patients with AECOPD

  Characteristics            Total, N   Alive, N (%)   Death, N (%)   *RR*                 *X*^2^       *P*-value
  -------------------------- ---------- -------------- -------------- -------------------- ------------ -----------
  **Age (years)**                       315            28                                  6.577        **0.160**
  ≤59                        23         23 (100)       0 (4.3)                                          
  60--69                     60         57 (95.0)      3 (5.0)        1                                 
  70--79                     112        105 (93.7)     7 (6.3)        1.25 (0.34--4.66)                 
  80--89                     125        110 (88.0)     15 (12.0)      2.40 (0.72--7.97)                 
  ≥90                        23         20 (87.0)      3 (13.0)       2.61 (0.57--12.00)                
  **Smoking**                                                                              **0.701**    0.704
  No                         88         97 (90.7)      10 (9.3)       1                                 
  Yes                        389        46 (90.2)      5 (9.8)        1.05 (0.38--2.91)                 
  Ever                                  172 (93.0)     13 (7.0)       0.75 (0.34--1.66)                 
  **Sex**                                                                                  0.551        0.458
  Male                       223        203 (91)       20 (9.0)       1                                 
  Female                     120        112 (93.3)     8 (6.7)        0.74 (0.37--1.64)                 
  **pH**                                                                                   **15.641**   0.000
  ≥7.35                      281        266 (94.7)     15 (5.3)       1                                 
  7.20--7.35                 57         46 (80.7)      11 (19.3)      3.62 (1.75--7.46)                 
  ≤7.20                      5          3 (60)         2 (40)         7.49 (2.30--24.41)                
  **PaCO~2~ (mmHg)**                                                                       **14.749**   0.000
  \<50                       261        248 (86.6)     13 (5.0)       1                                 
  ≥50                        82         67 (72)        15 (18.3)      3.67 (1.82--7.40)                 
  **PaO~2~ (mmHg)**                                                                        **13.732**   0.000
  ≥60                        305        286 (93.8)     19 (6.2)       1                                 
  \<60                       38         29 (76.3)      9 (23.7)       3.89 (1.85--7.79)                 
  **CHF**                                                                                  **27.498**   0.000
  No                         283        270 (95.4)     13 (4.6)       1                                 
  Yes                        60         45 (75)        15 (25)        5.44 (2.73--10.83)                
  **RD**                                                                                   **27.667**   0.000
  No                         302        286 (94.7)     16 (5.3)       1                                 
  Yes                        41         29 (70.7)      12 (29.3)      5.52 (2.82--10.84)                
  **D-dimer (mg/L)**                                                                       **31.008**   0.000
  \<985                      258        250 (96.9)     8 (3.1)        1                                 
  ≥985                       85         65 (76.5)      20 (23.5)      6.51 (3.06--13.83)                
  **FEV~1~ predicted**                                                                     2.040        0.564
  ≥80                        34         34 (100)       0 (0)                                            
  50--80                     139        122 (87.8)     17 (12.2)      1                                 
  30--50                     122        113 (92.6)     9 (7.4)        0.60 (0.28--1.30)                 
  \<30                       48         46 (95.8)      2 (4.2)        0.34 (0.08--1.42)                 
  **Frequent exacerbator**                                                                 1.99         0.1578
  No                         214        200            14             1                                 
  Yes                        129        115            14             1.37 (0.92--2.04)                 

**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CHF, congestive heart failure; PaCO~2~, arterial carbon dioxide tension; PaO~2~, arterial oxygen tension; RD, renal dysfunction; *RR*, relative risk.

###### 

Logistic regression analyses of the risk factors associated with hospital mortality in AECOPD patients

  Variable              B        SE      Wald     *P*-value   Exp (B)   95% CI for Exp (B)   
  --------------------- -------- ------- -------- ----------- --------- -------------------- --------
  D-dimer               1.685    0.503   11.218   **0.001**   5.395     2.012                14.465
  PaCO~2~ (\>50 mmHg)   0.983    0.608   2.618    0.106       2.673     0.812                8.794
  PaO~2~ (\<60 mmHg)    0.645    0.639   1.018    0.313       1.906     0.544                6.670
  **pH**                                                                                     
  pH (7.20--7.35)       0.617    1.411   0.191    0.662       1.853     0.117                29.444
  pH (−7.20)            0.572    0.613   0.871    0.351       1.773     0.533                5.899
  RD                    0.992    0.567   3.065    0.080       2.698     0.888                8.194
  CHF                   1.715    0.504   11.564   0.001       5.555     2.068                14.924
  Constant              −5.149   0.604   72.594   **0.000**   0.006                          

**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CI, confidence interval; CHF, congestive heart failure; PaCO~2~, arterial carbon dioxide tension; PaO~2~, arterial oxygen tension; RD, renal dysfunction; SE, standard error.

###### 

Univariate and multivariate Cox regression analysis evaluating the effect of serum D-dimer levels and confounders on 1-year mortality

  Variable                          Univariate analysis    Multivariate analysis                          
  --------------------------------- ---------------------- ----------------------- ---------------------- -------
  **Age (years)**                                          0.019                                          
  60--69                            2.78 (0.34--22.60)     0.339                   2.34 (0.29--19.14)     0.426
  70--79                            3.01 (0.40--22.92)     0.286                   1.96 (0.25--15.42)     0.523
  80--89                            5.50 (0.75--40.48)     0.094                   2.55 (0.33--19.84)     0.372
  ≥90                               9.65 (1.21--77.15)     0.033                   4.49 (0.53--38.07)     0.168
  ***%FEV~1~***                                            0.608                                          
  *GOLD 2*                          2.24 (0.68--7.42)      0.187                                          
  *GOLD 3*                          1.97 (0.59--6.63)      0.273                                          
  *GOLD 4*                          2.22 (0.60--8.20)      0.232                                          
  **pH**                                                                                                  
  7.20--7.35                        4.61 (1.11--19.13)     0.036                   1.17 (0.21--6.54)      0.858
  ≤7.20                             3.09 (1.77--5.40)      0.000                   1.83 (0.90--3.73)      0.096
  ***Smoker***                                                                                            
  *Yes*                             1.01 (0.47--2.13)      0.989                                          
  *Ever*                            0.70 (0.39--1.24)      0.224                                          
  **Gender (male)**                 1.18 (0.68--2.07)      0.557                                          
  *CHF (no/yes)*                    4.53 (2.68--7.65)      0.000                   2.99 (1.67--5.36)      0.000
  RD (yes)                          4.44 (2.54--7.77)      0.000                   2.21 (1.14--4.30)      0.02
  PaCO~2~ (\>50 mmHg)               2.41 (1.27--4.09)      0.001                   1.31 (0.64--2.68)      0.456
  PaO~2~ (\<60 mmHg)                2.46 (1.30--4.65)      0.006                   1.67 (0.82--3.43)      0.160
  D-dimer (\>985 µg/L)              3.48 (2.07--5.85)      0.001                   1.96 (1.05--3.65)      0.035
  CRP (mg/L)                        1.005 (1.001--1.008)   0.017                   1.004 (1.000--1.009)   0.064
  AECOPD for the past years (yes)   1.65 (0.98--2.80)      0.058                   1.38 (0.79--2.40)      0.258

**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CHF, congestive heart failure; CI, confidence interval; CRP, C-reactive protein; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; PaO~2~, arterial oxygen tension; PaCO~2~, arterial carbon dioxide tension; RD, renal dysfunction.
